Legal & General Group PLC Zymeworks Inc. Transaction History

Legal & General Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 22, 2022	SELL	$4.82 - $7.7 $82,277 - $131,439	-17,070 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.0 - $16.98 $15,000 - $42,450	2,500 Added 17.16%	17,070 $112,000
Q4 2021 Feb 14, 2022	BUY	$15.19 - $29.33 $88,329 - $170,553	5,815 Added 66.42%	14,570 $239,000
Q3 2021 Nov 15, 2021	BUY	$27.35 - $37.28 $199,518 - $271,957	7,295 Added 499.66%	8,755 $254,000
Q2 2020 Aug 14, 2020	BUY	$33.67 - $40.0 $49,158 - $58,400	1,460 New	1,460 $53,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $861M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.